Clinical Trials | December 12, 2025
Neurizon’s ALS drug regimen cleared for launch in Healey platform trial
The Healey ALS Platform Trial is a multicenter, double-blind, placebo-controlled
The Healey ALS Platform Trial is a multicenter, double-blind, placebo-controlled
At the trial’s pre-specified interim analysis, giredestrant achieved a hazard ratio of 0.70, marking a statistically significant improvement in invasive disease-free survival
The company had achieved the highest "A" rating in Climate Change
The product will be marketed by Dr. Reddy's Laboratories Inc.
The Phase 2 study tested two dose levels of pumitamig alongside four standard chemotherapy regimens across first
The agreement pairs Croda’s global footprint and “smart science” approach with Amino’s precision manufacturing capabilities
The new site marks the company’s first operation in the region
Zyrifa is indicated for patients with bone metastases stemming from a wide range of solid tumors
This strategic investment aims to bolster the company's position as a global leader in Vitamin D3 manufacturing
Formycon AG will develop, register, manufacture and supply the product, while Zydus Lifesciences Global FZE, United Arab Emirates will be responsible for the commercialization of FYB206 in the defined territories
Subscribe To Our Newsletter & Stay Updated
